Axsome Therapeutics (AXSM) Receivables (2022 - 2026)

Axsome Therapeutics (AXSM) has 5 years of Receivables data on file, last reported at $273.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 55.06% year-over-year to $273.2 million; the trailing twelve-month figure through Mar 2026 stood at $273.2 million (up 55.06% YoY), and the FY2025 full-year result was $246.7 million, up 58.63% from the prior year.
• Receivables climbed to $273.2 million in Q1 2026, from $246.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $273.2 million in Q1 2026 to a low of $16.2 million in Q2 2022.
• A 5-year average of $126.5 million and a median of $117.7 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables soared 413.75% in 2023 and soared 32.32% in 2024, its largest moves.
• Tracing AXSM's Receivables over 5 years: stood at $37.7 million in 2022, then jumped by 184.68% to $107.3 million in 2023, then soared by 32.32% to $142.0 million in 2024, then jumped by 73.71% to $246.7 million in 2025, then rose by 10.75% to $273.2 million in 2026.
• Business Quant data shows AXSM's Receivables at $273.2 million in Q1 2026, $246.7 million in Q4 2025, and $196.5 million in Q3 2025.